NeuroX1 is developing a target ID and drug discovery platform leveraging proprietary generative AI algorithms to create the next generation of therapeutics for neurological disorders. Our early-stage pipeline consists of several pre-clinical assets partnered with a variety of pharma companies and institutions.
-
Industry
-
Biotechnology Research
-
Company size
-
2-10 employees
-
Headquarters
-
Austin, TX
-
Type
-
Privately Held
-
Founded
-
2021
-
Specialties
-
generative drug discovery, biotechnology, neurology, neurodegenerative, rare disease, pediatric rare disease, AI, neuroscience, cancer, brain, generativeAI, Alzheimer's, Parkinson's, preclinical, MS, big pharma, partnerships, target ID, generative drugs, novel drugs, novel small molecules, future of drug discovery, inhibitors, neurosurgery, neural networks, platform technology, drug discovery platform, computational chemistry, computational biology, and target discovery